

# DECIPHER BLADDER TURBT

DECIPHER BLADDER TURBT REQUISITION FORM  
 Fax: 855.324.2768 (Toll-Free) or 858.408.7420 (Direct)  
 Email: orders@decipherbio.com

BLUE HIGHLIGHTED FIELDS ARE REQUIRED

## PATIENT INFORMATION

Patient Name			
DOB (MM/DD/YYYY)	Sex <input type="checkbox"/> M <input type="checkbox"/> F	Patient Medical Record #	Race/Ethnicity

## ORDERING PHYSICIAN INFORMATION

Account #	Office/Practice/Institution Name
Address	
Telephone	Fax
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/>	<input type="checkbox"/>
<input type="checkbox"/> Other _____	

## DECIPHER TESTING

<input type="checkbox"/> <b>Decipher Bladder TURBT</b> <small>See reverse side for test description.</small>			
Specimen Type <input type="checkbox"/> TURBT (only TURBT specimens are accepted for testing)	Date of TURBT Used for Radical Cystectomy Decision (MM/DD/YYYY)	Histology Type (samples with neuroendocrine/small cell features and adenocarcinomas are not accepted) <input type="checkbox"/> Urothelial/Transitional Cell Carcinoma <i>Select if present:</i> <input type="checkbox"/> Squamous Differentiation <input type="checkbox"/> Glandular Differentiation <input type="checkbox"/> Micropapillary <input type="checkbox"/> Other	
Lymph-Vascular Invasion <input type="checkbox"/> Not Identified <input type="checkbox"/> Present <input type="checkbox"/> Indeterminate <input type="checkbox"/> Not Reported	Evidence of Distant Metastasis <input type="checkbox"/> Yes <input type="checkbox"/> No	Tumor Type (check all that apply) <input type="checkbox"/> Muscle Invasive Carcinoma <input type="checkbox"/> Carcinoma In-Situ <input type="checkbox"/> Non-Muscle Invasive Carcinoma	Tumor Grade <input type="checkbox"/> Low Grade <input type="checkbox"/> High Grade
Prior radiation therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No		Prior chemotherapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	

## PATHOLOGY / SPECIMEN INFORMATION. Complete only if pathology report is not attached.

Laboratory	Specimen ID	Telephone	Fax
------------	-------------	-----------	-----

## PHYSICIAN SIGNATURE

I confirm that this test is medically necessary and results will be used for treatment decisions and medical management for the patient. I hereby authorize testing and an informed consent has been obtained. I understand that, as part of the Decipher testing, additional genomic information will be collected as part of Decipher GRID and may be provided as research use only (RUO) data.	
Ordering Physician Signature	Date (MM/DD/YYYY)

## GRID PROFILE (See description on reverse)

<input type="checkbox"/> Check here if the patient has authorized you to receive their GRID Profile, which is for RUO and not to be used for treatment decision or medical management.
--

## BILLING INFORMATION NOTE: DECIPHER BLADDER IS NOT COVERED BY INSURANCE AND MUST BE PAID IN ADVANCE

Name of Person Providing Payment <input type="checkbox"/> Patient <input type="checkbox"/> Other _____	Telephone Number	Email Address
---	------------------	---------------

### THE FOLLOWING MUST BE ATTACHED

- Demographic/face sheet
- Pathology report



## DECIPHER BLADDER TURBT TEST DESCRIPTION

Decipher® Bladder TURBT, a microarray gene expression assay, employs Decipher Biosciences' proprietary Genomic Subtyping Classifier (GSC) to classify formalin-fixed, paraffin-embedded (FFPE) bladder tumor samples into one of four molecular subtypes (Luminal, Luminal Infiltrated, Basal, Basal Claudin-Low) based on functional molecular pathways. The GSC was developed and validated in 305 neoadjuvant chemotherapy and 476 radical cystectomy alone patients from 10 cancer centers in North America and Europe. GSC uses RNA expression values to calculate multinomial probabilities of the tumor sample belonging to each of the four molecular subtypes. The higher the score, the more certain the sample will belong to assigned subtype. The patient tumor samples are classified as belonging to the subtype with the highest probability. The Decipher GSC molecular subtypes are based on a consensus classification derived from The Cancer Genome Atlas project and other previously published schema. The GSC has AUCs ranging from 0.85 to 0.97 for classifying a tumor sample into one of the four molecular subtypes in two independent validation cohorts (n=558). Results from Decipher Bladder are intended for use by the physician and patient as an adjunct to conventional clinical variables and models currently used for determining prognosis of patients diagnosed with muscle invasive bladder cancer using FFPE TURBT specimens.

## GRID PROFILE DESCRIPTION

The Decipher assay collects up to 1.4 million data points for each patient when the Decipher test is performed, and such data is used to create the GRID Tumor RNA Expression Profile (GRID Profile). The GRID Profile is a summation of genomic signatures and biomarkers for Research Use Only. Physicians can access their patient's GRID Profile with their patient's authorization (in a form and format that complies with HIPAA and state law) by contacting Decipher Biosciences. The genomic data will be securely stored in the Decipher GRID database and will be de-identified for any research use. For more information, please visit: [www.decipherbio.com](http://www.decipherbio.com)

## ORDER ACCEPTANCE CRITERIA

Orders submitted to Decipher Biosciences for Decipher Bladder TURBT testing must meet the criteria below.

- Specimen Type: TURBT (Trans-Urethral Resection of Bladder Tumor)
- Tumor Type: Muscle Invasive Carcinoma
- Primary Histology Type: Urothelial/Transitional Cell Carcinoma
- No evidence of distant metastasis
- No prior neoadjuvant chemotherapy

Testing is performed by Decipher Corp., a Decipher Biosciences company, located at 10355 Science Center Drive, Suite 240, San Diego, CA 92121.

The Decipher Corp. laboratory is licensed for high complexity testing under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).

